Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.50 |
| ▸ | GUSB | P08236 | 3/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL1232434 | 0.91 | GPR84 (0.50) | GPR84HTR2ATRPM8NR4A2CSNK2A1 | |
| SCHEMBL28520808 | 0.91 | GPR84 (0.50) | GPR84HTR2ATRPM8NR4A2CSNK2A1 | |
| Acetic Acid SCHEMBL2543914 | 0.89 | NR4A2 (0.55) | GPR84HTR2ATRPM8NR4A2CSNK2A1 | |
| Acetic Acid SCHEMBL23525629 | 0.89 | NR4A2 (0.55) | GPR84HTR2ATRPM8NR4A2CSNK2A1 | |
| SCHEMBL2804219 | 0.83 | CYP2A6 (0.55) | GPR84GUSBSLC6A4IDO1 | |
| SCHEMBL28207416 | 0.78 | GPR84 (0.62) | GPR84HTR2ATRPM8NR4A2CSNK2A1 | |
| SCHEMBL5429556 | 0.78 | GPR84 (0.62) | GPR84HTR2ATRPM8NR4A2CSNK2A1 | |
| SCHEMBL30686491 | 0.78 | HTR2C (0.56) | HTR2ASLC6A4MEN1MAPTKMT2A | |
| SCHEMBL5259883 | 0.78 | HTR2C (0.56) | HTR2ASLC6A4MEN1MAPTKMT2A | |
| B-D-Galactose SCHEMBL27919531 | 0.78 | ATM (0.44) | GPR84HTR2ATRPM8NR4A2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 507 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240084002-A1 | METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2024-03-14 | — | — | US | claimed |
| EP-4255423-A1 | METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION | Lankenau Institute for Medical Research (US) | 2023-10-11 | — | — | EP | claimed |
| CN-116806149-A | Methods and compositions for treating pathological conditions involving neovascularization using IDO 1-dependent angiogenic cells | 兰肯瑙医学研究所 | 2023-09-26 | — | — | CN | claimed |
| US-11752131-B2 | Methods and pharmaceutical compositions for the treatment of obesity | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2023-09-12 | — | — | US | claimed |
| WO-2023161230-A1 | THERMOSTABLE GLYCOSYLTRANSFERASE VARIANTS | DANMARKS TEKNISKE UNIVERSITET (DK) | 2023-08-31 | — | — | WO | claimed |
| WO-2022125553-A1 | METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2022-06-16 | — | — | WO | claimed |
| EP-2718458-B1 | NOVEL METHOD FOR DETECTION OF BETA-D-GLUCURONIDASE | BIOSYNTH AG (CH) | 2015-07-08 | — | — | EP | claimed |
| EP-2084293-B1 | GENETICALLY ENGINEERED BIOLOGICAL INDICATOR | AMERICAN STERILIZER CO (US) | 2014-08-13 | — | — | EP | claimed |
| US-20140212905-A1 | Novel Method for Detection of Beta-D-Glucuronidase | BIOSYNTH AG (CH) | 2014-07-31 | — | — | US | claimed |
| EP-2718458-A1 | NOVEL METHOD FOR DETECTION OF BETA-D-GLUCURONIDASE | Biosynth AG (CH) | 2014-04-16 | — | — | EP | claimed |
| US-20020182600-A1 | Method for assaying biological and other constituents using synthetic nucleounits in lateral flow, liquid, and dry chemistry techniques | SMITH JACK V (US) | 2002-12-05 | — | — | US | claimed |
| US-6420552-B1 | GENERATING CHROMOGENIC GLYCOSIDES; OBTAIN NEURAMIC ACID DERIVATIVE, ALKYLATE, DEPROTECT HYDROXYL GROUPS, ACTIVATE ANOMERIC CARBON, INCUBATE WITH CHROMOGEN, REGENERATE HYDROXYL GROUPS, RECOVER CHROMOGENIC GLYCOSIDE | ZYMETX, INC. | 2002-07-16 | — | — | US | claimed |
| WO-2002053705-A1 | CULTURE MEDIUM FOR DETECTING BACTERIA OF LISTERIA GENUS | RAMBACH ALAIN (FR) | 2002-07-11 | — | — | WO | claimed |
| WO-2002000922-A1 | VIBRIO BACTERIA DETECTION AND/OR DIFFERENTIATION | RAMBACH ALAIN (FR) | 2002-01-03 | — | — | WO | claimed |
| US-6303764-B1 | EFFICIENT PREPARATION OF KETOSIDE WHICH IS SUBSTRATE FOR NEURAMINIDASES; FOR USE IN DETECTION OF INFLUENZA VIRUS TYPES A AND B | ZYMETX, INC. | 2001-10-16 | — | — | US | claimed |
| US-6165743-A | Culture medium for revealing enterohemorrhagic E. coli bacteria and procedure therefor | RAMBACH ALAIN (FR) | 2000-12-26 | — | — | US | claimed |
| US-5962251-A | INTRODUCING AT LEAST TWO CHROMOGENS WHICH ARE ENZYME SUBSTRATES FOR A MICROORGANISM STRAIN INTO CULTURE MEDIUM, IDENTIFYING ACCESSORY COLOR PRODUCED BY ENZYMATIC ACTIVITY | RAMBACH ALAIN (FR) | 1999-10-05 | — | — | US | claimed |
| EP-0711360-B1 | Process for the identification of microorganisms using at least two chromogens | RAMBACH ALAIN (FR) | 1998-03-11 | — | — | EP | claimed |
| US-5716799-A | QUALITATIVE COLORIMETRIC ANALYSIS | RAMBACH ALAIN (FR) | 1998-02-10 | — | — | US | claimed |
| EP-0711359-B1 | MICROORGANISM IDENTIFICATION METHOD USING A MEDIUM CONTAINING ADDED CARBOHYDRATE | RAMBACH ALAIN (FR) | 1997-05-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240084002-A1 | METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION | IDO1, IDO2, TIE1 | GPR84 1810/4885HTR2A 3120/4885TRPM8 3436/4885 |
| US-11752131-B2 | Methods and pharmaceutical compositions for the treatment of obesity | IDO1, IDO2, GPR119 | GPR84 1077/4885HTR2A 210/4885TRPM8 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.